NCT04740580Active, not recruitingEarly phase 1
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 2 Feb 2021
- Start date
- 15 Feb 2022
- Primary completion date
- 30 Aug 2026
- Lead sponsor
- Baylor College of Medicine
- Diseases
- Alzheimer disease
- NCT number
- NCT04740580
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 52
- From 15 Feb 2022 to the primary completion date, 30 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- use of insulin medications;
Other illness
- untreated thyroid disease;
- history of stroke, brain tumor, active heart failure or active cancer (removable basal cell cancers will not be an exclusion criteria);
- untreated depression or other severe psychiatric disorders;
Lab values
- creatinine levels \>1.5 mg/dL;
- hemoglobin concentration \<11.0 g/dL;
- known liver disease, or AST/ALT level \>2x ULN;
Other
- hospitalization in past 3 months;
- pregnancy or nursing (unlikely in this population)
Who the study is looking for
- Age 55-85 years;
- Gradual and progressive memory loss for more than 1 year, with a Montreal Cognitive Assessment score of 10-20;
- Amyloid positivity on PET scan;
- Availability of a study partner.
Age in the registry: 55 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Baylor College of Medicine Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.